CA-074Me, a cathepsin B inhibitor, decreases APP accumulation and protects primary rat cortical neurons treated with okadaic acid

Neuroscience Letters

Volumn 548, Issue , 2013, Pages 222-227

  Cho, Kwangmin ^a   Yoon, Seung Yong ^a   Choi, Jung Eun ^a   Kang, Hoe Jin ^a   Jang, He Yoon ^a   Kim, Dong Hou ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Alzheimer's disease; CA074 Me; Lysosome; Okadaic acid

Indexed keywords

AMYLOID PRECURSOR PROTEIN; CA 074ME; CALPAIN; CATHEPSIN B INHIBITOR; CATHEPSIN D; CATHEPSIN L; FODRIN; OKADAIC ACID; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; BRAIN CELL; CELL DEATH; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; LYSOSOME; NONHUMAN; PRIORITY JOURNAL; RAT; UPREGULATION;

ALZHEIMER'S DISEASE; CA074-ME; LYSOSOME; OKADAIC ACID;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; CATHEPSIN B; CELLS, CULTURED; DIPEPTIDES; DOWN-REGULATION; NEOCORTEX; NEURONS; NEUROPROTECTIVE AGENTS; OKADAIC ACID; RATS; TREATMENT OUTCOME;

EID: 84880134745     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2013.05.056     Document Type: Article

References (34)

1. Adamec E., Mohan P., Vonsattel J.P., Nixon R.A. Calpain activation in neurodegenerative diseases: confocal immunofluorescence study with antibodies specifically recognizing the active form of calpain 2. Acta Neuropathologica 2002, 104:92-104.
2. Adamec E., Mohan P.S., Cataldo A.M., Vonsattel J.P., Nixon R.A. Up-regulation of the lysosomal system in experimental models of neuronal injury: implications for Alzheimer's disease. Neuroscience 2000, 100:663-675.
3. An W.L., Cowburn R.F., Li L., Braak H., Alafuzoff I., Iqbal K., Iqbal I.G., Winblad B., Pei J.J. Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's disease. American Journal of Pathology 2003, 163:591-607.
4. Arendt T., Holzer M., Fruth R., Bruckner M.K., Gartner U. Phosphorylation of tau, Abeta-formation, and apoptosis after in vivo inhibition of PP-1 and PP-2A. Neurobiology of Aging 1998, 19:3-13.
5. Arias C., Sharma N., Davies P., Shafit-Zagardo B. Okadaic acid induces early changes in microtubule-associated protein 2 and tau phosphorylation prior to neurodegeneration in cultured cortical neurons. Journal of Neurochemistry 1993, 61:673-682.
6. Bendiske J., Bahr B.A. Lysosomal activation is a compensatory response against protein accumulation and associated synaptopathogenesis-an approach for slowing Alzheimer disease?. Journal of Neuropathology and Experimental Neurology 2003, 62:451-463.
7. Bi X., Zhou J., Lynch G. Lysosomal protease inhibitors induce meganeurites and tangle-like structures in entorhinohippocampal regions vulnerable to Alzheimer's disease. Experimental Neurology 1999, 158:312-327.
8. Boya P., Gonzalez-Polo R.A., Poncet D., Andreau K., Vieira H.L., Roumier T., Perfettini J.L., Kroemer G. Mitochondrial membrane permeabilization is a critical step of lysosome-initiated apoptosis induced by hydroxychloroquine. Oncogene 2003, 22:3927-3936.
9. Cataldo A.M., Barnett J.L., Berman S.A., Li J., Quarless S., Bursztajn S., Lippa C., Nixon R.A. Gene expression and cellular content of cathepsin D in Alzheimer's disease brain: evidence for early up-regulation of the endosomal-lysosomal system. Neuron 1995, 14:671-680.
10. Cataldo A.M., Barnett J.L., Pieroni C., Nixon R.A. Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer's disease: neuropathologic evidence for a mechanism of increased beta-amyloidogenesis. Journal of Neuroscience 1997, 17:6142-6151.
11. Cataldo A.M., Hamilton D.J., Barnett J.L., Paskevich P.A., Nixon R.A. Properties of the endosomal-lysosomal system in the human central nervous system: disturbances mark most neurons in populations at risk to degenerate in Alzheimer's disease. Journal of Neuroscience 1996, 16:186-199.
12. Cataldo A.M., Paskevich P.A., Kominami E., Nixon R.A. Lysosomal hydrolases of different classes are abnormally distributed in brains of patients with Alzheimer disease. Proceedings of the National Academy of Sciences of the United States of America 1991, 88:10998-11002.
13. Gomez-Isla T., Hollister R., West H., Mui S., Growdon J.H., Petersen R.C., Parisi J.E., Hyman B.T. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Annals of Neurology 1997, 41:17-24.
14. Hook G., Hook V., Kindy M. The cysteine protease inhibitor, E64d, reduces brain amyloid-β and improves memory deficits in Alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1, β-secretase activity. Journal of Alzheimer's Disease 2011, 26:387-408.
15. Hook V., Kindy M., Hook G. Cysteine protease inhibitors effectively reduce in vivo levels of brain beta-amyloid related to Alzheimer's disease. Biological Chemistry 2007, 388:247-252.
16. Hook V.Y., Kindy M., Hook G. Inhibitors of cathepsin B improve memory and reduce beta-amyloid in transgenic Alzheimer disease mice expressing the wild-type, but not the Swedish mutant, beta-secretase site of the amyloid precursor protein. Journal of Biological Chemistry 2008, 283:7745-7753.
17. Lee S., Sato Y., Nixon R.A. Lysosomal proteolysis inhibition selectively disrupts axonal transport of degradative organelles and causes an Alzheimer's-like axonal dystrophy. Journal of Neuroscience 2011, 31:7817-7830.
18. Malchiodi-Albedi F., Petrucci T.C., Picconi B., Iosi F., Falchi M. Protein phosphatase inhibitors induce modification of synapse structure and tau hyperphosphorylation in cultured rat hippocampal neurons. Journal of Neuroscience Research 1997, 48:425-438.
19. Mihalik R., Imre G., Petak I., Szende B., Kopper L. Cathepsin B-independent abrogation of cell death by CA-074-OMe upstream of lysosomal breakdown. Cell Death and Differentiation 2004, 11:1357-1360.
20. Mueller-Steiner S., Zhou Y., Arai H., Roberson E.D., Sun B., Chen J., Wang X., Yu G., Esposito L., Mucke L., Gan L. Antiamyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer's disease. Neuron 2006, 51:703-714.
21. Nimmrich V., Reymann K.G., Strassburger M., Schoder U.H., Gross G., Hahn A., Schoemaker H., Wicke K., Moller A. Inhibition of calpain prevents NMDA-induced cell death and beta-amyloid-induced synaptic dysfunction in hippocampal slice cultures. British Journal of Pharmacology 2010, 159:1523-1531.
22. Nixon R.A., Cataldo A.M. Lysosomal system pathways: genes to neurodegeneration in Alzheimer's disease. Journal of Alzheimer's Disease 2006, 9:277-289.
23. Saito K., Elce J.S., Hamos J.E., Nixon R.A. Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer disease: a potential molecular basis for neuronal degeneration. Proceedings of the National Academy of Sciences of the United States of America 1993, 90:2628-2632.
24. Sun L., Liu S.Y., Zhou X.W., Wang X.C., Liu R., Wang Q., Wang J.Z. Inhibition of protein phosphatase 2A- and protein phosphatase 1-induced tau hyperphosphorylation and impairment of spatial memory retention in rats. Neuroscience 2003, 118:1175-1182.
25. Taniguchi S., Fujita Y., Hayashi S., Kakita A., Takahashi H., Murayama S., Saido T.C., Hisanaga S., Iwatsubo T., Hasegawa M. Calpain-mediated degradation of p35 to p25 in postmortem human and rat brains. FEBS Letters 2001, 489:46-50.
26. Traganos F., Darzynkiewicz Z. Lysosomal proton pump activity: supravital cell staining with acridine orange differentiates leukocyte subpopulations. Methods in Cell Biology 1994, 41:185-194.
27. Tsuji T., Shimohama S., Kimura J., Shimizu K. m-Calpain (calcium-activated neutral proteinase) in Alzheimer's disease brains. Neuroscience Letters 1998, 248:109-112.
28. Williams A., Sarkar S., Cuddon P., Ttofi E.K., Saiki S., Siddiqi F.H., Jahreiss L., Fleming A., Pask D., Goldsmith P., O'Kane C.J., Floto R.A., Rubinsztein D.C. Novel targets for Huntington's disease in an mTOR-independent autophagy pathway. Nature Chemical Biology 2008, 4:295-305.
29. Yamashima T., Oikawa S. The role of lysosomal rupture in neuronal death. Progress in Neurobiology 2009, 89:343-358.
30. Yamashima T., Tonchev A.B., Tsukada T., Saido T.C., Imajoh-Ohmi S., Momoi T., Kominami E. Sustained calpain activation associated with lysosomal rupture executes necrosis of the postischemic CA1 neurons in primates. Hippocampus 2003, 13:791-800.
31. Yang D.S., Stavrides P., Mohan P.S., Kaushik S., Kumar A., Ohno M., Schmidt S.D., Wesson D., Bandyopadhyay U., Jiang Y., Pawlik M., Peterhoff C.M., Yang A.J., Wilson D.A., St George-Hyslop P., Westaway D., Mathews P.M., Levy E., Cuervo A.M., Nixon R.A. Reversal of autophagy dysfunction in the TgCRND8 mouse model of Alzheimer's disease ameliorates amyloid pathologies and memory deficits. Brain 2011, 134:258-277.
32. Yoon S.Y., Choi J.E., Ham J.H., Choe H., Lee H.S., Kim D.H. zVLL-CHO at low concentrations acts as a calpain inhibitor to protect neurons against okadaic acid-induced neurodegeneration. Neuroscience Letters 2012, 509:33-38.
33. Yoon S.Y., Choi J.E., Kweon H.S., Choe H., Kim S.W., Hwang O., Lee H., Lee J.Y., Kim D.H. Okadaic acid increases autophagosomes in rat neurons: implications for Alzheimer's disease. Journal of Neuroscience Research 2008, 86:3230-3239.
34. Yu W.H., Cuervo A.M., Kumar A., Peterhoff C.M., Schmidt S.D., Lee J.H., Mohan P.S., Mercken M., Farmery M.R., Tjernberg L.O., Jiang Y., Duff K., Uchiyama Y., Naslund J., Mathews P.M., Cataldo A.M., Nixon R.A. Macroautophagy-a novel beta-amyloid peptide-generating pathway activated in Alzheimer's disease. Journal of Cell Biology 2005, 171:87-98.